SA Biotech secures RMB100M in Series A Funding
As one of the first batch of NUSRI's incubators, SA Biotech has closed its Series A investment round led by Matrix Partners China, with participation from Apex Capital.
SA Biotech was founded in Suzhou in 2012 and started its incubation at NUSRI. Under the nurturing of BLOCK71 Suzhou, SA Biotech has grown up into a leading company in animal vaccines in China. To date, the company has developed various vaccine products such as porcine circoviral genetic engineered vaccine, foot-and-mouth genetic engineered vaccine, and aquatic genetic engineered vaccine.
Prof. Adam Yuan, the founder of SA Biotech, said: “SA Biotech is the very first one to develop animal vaccines in China. We hope we can bring out the new generation of innovative vaccines with high efficiency and low cost into the market to benefit the breeding industry in China soon.”